Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has initiated a Phase 1 clinical trial for the Tengion Neo-Urinary Conduit™ in bladder cancer patients requiring bladder removal. The Company has completed two Phase 2 human clinical trials in the United States with its Tengion Neo-Bladder Augment™ for children with neurogenic bladder due to spina bifida and in adults with neurogenic ...